Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Pergola: boosting visualization and analysis of longitudinal data by unlocking genomic analysis tools

  • Espinosa-Carrasco, José
  • Erb, Ionas
  • Hermoso Pulido, Antonio
  • Ponomarenko, Julia
  • Dierssen, Mara
  • Notredame, Cedric
The growing appetite of behavioral neuroscience for automated data production is prompting the need for new computational standards allowing improved interoperability, reproducibility, and shareability. We show here how these issues can be solved by repurposing existing genomic formats whose structure perfectly supports the handling of time series. This allows existing genomic analysis and visualization tools to be deployed onto behavioral data. As a proof of principle, we implemented the conversion procedure in Pergola, an open source software, and used genomics tools to reproduce results obtained in mouse, fly, and worm. We also show how common genomics techniques such as principal component analysis, hidden Markov modeling, and volcano plots can be deployed on the reformatted behavioral data. These analyses are easy to share because they depend on the scripting of public software. They are also easy to reproduce thanks to their integration within Nextflow, a workflow manager using containerized software., We acknowledge the support of the “Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat i del Fons Social Europeu,” Spanish Ministry of Economy, Industry and Competitiveness (MEIC) under grant numbers BFU2014-55062-P and BFU2017-88264-P, the EMBL partnership, FEDER, the “Centro de Excelencia Severo Ochoa” Programme, and the CERCA Programme/Generalitat de Catalunya. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 635290-PanCanRisk and OpenRiskNet_731076. This reflects only the author's view and the funder is not responsible for any use that may be made of the information it contains. M.D. is supported by DIUE de la Generalitat de Catalunya (Grups consolidats SGR 2017/926), the Fondation Jérôme Lejeune (Paris, France), MINECO (SAF2013-49129-C2-1-R; SAF2016-79956-R), CDTI (“Smartfoods”) and EU (EraNet Neuron PCIN-2013-060 and JPND AC17/00006), and the Catalan foundation “La Marató de TV3” (#2016/20-30). The CIBER of Rare Diseases is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome

  • Torre Fornell, Rafael de la
  • De Sola Llopis, Susana
  • Xicota Vila, Laura, 1987-
  • Cuenca Royo, Aida Ma, 1981-
  • Rodriguez, Joan
  • Gomis González, Maria, 1988-
  • Hernández, Gimena
  • Del Hoyo Soriano, Laura
  • Ozaita Mintegui, Andrés, 1969-
  • Dierssen, Mara
  • TESXF Study Group
  • Principe, Alessandro
  • Espadaler, Josep María
  • Roca, Laia
  • Del Hoyo Soriano, Laura
  • Farré Albaladejo, Magí
  • Fitó Colomer, Montserrat
  • León Jorba, Alba
  • Banea, Ovideo
  • Maldonado, Rafael, 1961-
  • Busquets Garcia, Arnau, 1985-
Background & aims: Despite the wide spectrum of experimental compounds tested in clinical trials, there is still no proven pharmacological treatment available for Fragile-X syndrome (FXS), since several targeted clinical trials with high expectations of success have failed to demonstrate significant improvements. Here we tested epigallocatechin-3-gallate (EGCG) as a treatment option for ameliorating core cognitive and behavioral features in FXS. Methods: We conducted preclinical studies in Fmr1 knockout mice (Fmr1−/y) using novel object-recognition memory paradigm upon acute EGCG (10 mg/kg) administration. Furthermore we conducted a double-blind placebo-controlled phase I clinical trial (TESXF; NCT01855971). Twenty-seven subjects with FXS (18–55 years) were administered of EGCG (5–7 mg/kg/day) combined with cognitive training (CT) during 3 months with 3 months of follow-up after treatment discontinuation. Results: Preclinical studies showed an improvement in memory using the Novel Object Recognition paradigm. We found that FXS patients receiving EGCG + CT significantly improved cognition (visual episodic memory) and functional competence (ABAS II-Home Living skills) in everyday life compared to subjects receiving Placebo + CT. Conclusions: Phase 2 clinical trials in larger groups of subjects are necessary to establish the therapeutic potential of EGCG for the improvement of cognition and daily life competences in FXS., This work was supported by the Spanish Ministry of Economy and Competitiveness; ‘Centro de Excelencia Severo Ochoa 2013-2017’; the ‘Centres de Recerca de Catalunya’ Programme / Generalitat de Catalunya’; the Centro de Investigación Biomédica en Red Enfermedades Raras (CIBER) of Rare Diseases; DIUE de la Generalitat de Catalunya [Grups consolidats SGR 2014/1125]; Ministerio de Economía, Industria y Competitividad de España MINECO [SAF2013-49129-C2-1-R and SAF2016-79956-R].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Pergola-web: a web server for the visualization and analysis of longitudinal behavioral data using repurposed genomics tools and standards

  • Espinosa-Carrasco, José
  • Hermoso Pulido, Antonio
  • Erb, Ionas
  • Dierssen, Mara
  • Ponomarenko, Julia
  • Notredame, Cedric
We present a new web application to query and visualize time-series behavioral data: the Pergola web-server. This server provides a user-friendly interface for exploring longitudinal behavioral data taking advantage of the Pergola Python library. Using the server, users can process the data applying some basic operations, such as binning or grouping, while formatting the data into existing genomic formats. Thanks to this repurposing of genomics standards, the application automatically renders an interactive data visualization based on sophisticated genome visualization tools. Our tool allows behavioral scientists to share, display and navigate complex behavioral data comprising multiple individuals and multiple data types, in a scalable and flexible manner. A download option allows for further analysis using genomic tools. The server can be a great resource for the field in a time where behavioral science is entering a data-intensive cycle thanks to high-throughput behavioral phenotyping platforms. Pergola is publicly available at http://pergola.crg.eu/., 'Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat i del Fons Social Europeu', Spanish Ministry of Economy, Industry and Competitiveness (MEIC) [BFU2014-55062-P, BFU2017-88264-P]; EMBL partnership, FEDER, the ‘Centro de Excelencia Severo Ochoa’ Programme; CERCA Programme/Generalitatde Catalunya; European Union's Horizon 2020 research and innovation program [635290-PanCanRisk and OpenRiskNet_731076]; DIUE de la Generalitat de Catalunya [Grups consolidatsSGR 2017/926]; Fondation Jérôme Lejeune (Paris, France), MINECO [SAF2013-49129-C2-1-R;SAF2016-79956-R]; CDTI (‘Smartfoods’) and EU [EraNet Neuron PCIN-2013-060 and JPND AC17/00006]; Catalan foundation ‘La Marato′de TV3’ [2016/20-30]; CIBER of Rare Diseases is an initiative of the ISCIII. Funding for open access charge: CRG institutional core funding.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome

  • Navarro-Romero, Alba
  • Vázquez-Oliver, Anna
  • Gomis González, Maria, 1988-
  • Garzón-Montesinos, Carlos
  • Falcón-Moya, Rafael
  • Pastor, Antonio
  • Martín García, Elena, 1975-
  • Pizarro Lozano, Mª Nieves
  • Busquets Garcia, Arnau, 1985-
  • Revest, Jean-Michel
  • Piazza, Pier Vincenzo
  • Bosch, Fatima
  • Dierssen, Mara
  • Torre Fornell, Rafael de la
  • Rodríguez-Moreno, Antonio
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Intellectual disability is the most limiting hallmark of Down syndrome, for which there is no gold-standard clinical treatment yet. The endocannabinoid system is a widespread neuromodulatory system involved in multiple functions including learning and memory processes. Alterations of this system contribute to the pathogenesis of several neurological and neurodevelopmental disorders. However, the involvement of the endocannabinoid system in the pathogenesis of Down syndrome has not been explored before. We used the best-characterized preclinical model of Down syndrome, the segmentally trisomic Ts65Dn model. In male Ts65Dn mice, cannabinoid type-1 receptor (CB1R) expression was enhanced and its function increased in hippocampal excitatory terminals. Knockdown of CB1R in the hippocampus of male Ts65Dn mice restored hippocampal-dependent memory. Concomitant with this result, pharmacological inhibition of CB1R restored memory deficits, hippocampal synaptic plasticity and adult neurogenesis in the subgranular zone of the dentate gyrus. Notably, the blockade of CB1R also normalized hippocampal-dependent memory in female Ts65Dn mice. To further investigate the mechanisms involved, we used a second transgenic mouse model overexpressing a single gene candidate for Down syndrome cognitive phenotypes, the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). CB1R pharmacological blockade similarly improved cognitive performance, synaptic plasticity and neurogenesis in transgenic male Dyrk1A mice. Our results identify CB1R as a novel druggable target potentially relevant for the improvement of cognitive deficits associated with Down syndrome., A.N.-R. is the recipient of a predoctoral fellowship (Ministerio de Educación y Cultura, Spain). A.V.-O. is the recipient of a predoctoral fellowship from Jérôme Lejeune Foundation, France (Spanish Delegation). M.G.-G. was partially supported by FRAXA Research Foundation, United States. A.B-G. was the recipient of a predoctoral fellowship (Ministerio de Educación y Cultura). This study was supported by Jérôme Lejeune Foundation (French Delegation) to A.O.; Instituto de Salud Carlos III, Spain (#RD16/0017/0020) to R.M.; Ministerio de Economía, Innovación y Competitividad (MINECO), Spain (#BFU2015-68568-P to A.O., #SAF2014-59648-P and #SAF2017- 84060-R to R.M.; SAF2016-79956-R to M.D.); Catalan Foundation ‘La Marató de TV3’, Spain (#2016/20-30) to E.M.-G.; Junta de Andalucía, Spain (CVI-7290 to A.R.-M.); Generalitat de Catalunya, Spain (2014SGR-1547 and 2017SGR-669 to R.M.; 2014SGR-1125 to M.D.) and ICREA (Institució Catalana de Recerca i Estudis Avançats, Spain) Academia to A.O. and R.M. Grant “Unidad de Excelencia María de Maeztu”, funded by the MINECO (#MDM-2014-0370); PLAN E, Spain (Plan Español para el Estímulo de la Economía y el Empleo); FEDER, European Commission funding is also acknowledged
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome

  • Starbuck, John M.
  • Llambrich, Sergi
  • González, Rubén
  • Albaigès-Ràfols, Júlia
  • Sarlé, Anna
  • Wouters, Jens
  • González, Alejandro
  • Sevillano, Xavier
  • Sharpe, James
  • Torre Fornell, Rafael de la
  • Dierssen, Mara
  • Velde, Greetje Vande
  • Martínez Abadías, Neus
Trisomy of human chromosome 21 (Down syndrome, DS) alters development of multiple organ systems, including the face and underlying skeleton. Besides causing stigmata, these facial dysmorphologies can impair vital functions such as hearing, breathing, mastication, and health. To investigate the therapeutic potential of green tea extracts containing epigallocatechin-3-gallate (GTE-EGCG) for alleviating facial dysmorphologies associated with DS, we performed an experimental study with continued pre- and postnatal treatment with two doses of GTE-EGCG supplementation in a mouse model of DS, and an observational study of children with DS whose parents administered EGCG as a green tea supplement. We evaluated the effect of high (100 mg/kg/day) or low doses (30 mg/kg/day) of GTE-EGCG, administered from embryonic day 9 to post-natal day 29, on the facial skeletal development in the Ts65Dn mouse model. In a cross-sectional observational study, we assessed the facial shape in DS and evaluated the effects of self-medication with green tea extracts in children from 0 to 18 years old. The main outcomes are 3D quantitative morphometric measures of the face, acquired either with micro-computed tomography (animal study) or photogrammetry (human study). The lowest experimentally tested GTE-EGCG dose improved the facial skeleton morphology in a mouse model of DS. In humans, GTE-EGCG supplementation was associated with reduced facial dysmorphology in children with DS when treatment was administered during the first 3 years of life. However, higher GTE-EGCG dosing disrupted normal development and increased facial dysmorphology in both trisomic and euploid mice. We conclude that GTE-EGCG modulates facial development with dose-dependent effects. Considering the potentially detrimental effects observed in mice, the therapeutic relevance of controlled GTE-EGCG administration towards reducing facial dysmorphology in young children with Down syndrome has yet to be confirmed by clinical studies., We acknowledge support from a 2016 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation IN[16]_CMA_BIO_0096 (NMA). We also acknowledge grant support from the following: CRG Awards for Collaborative Research Proposals, CRG Awards 2015-005822 (NMA, JA), Marguerite-Marie Delacroix Foundation fellowship (SL), Jerome Lejeune Foundation, #1782 (GVV, NMA), University of Central Florida start-up funds (JMS), American Association of Physical Anthropologists Professional Development Program Grant (JMS), Flemish Research Foundation (FWO) fellowship (GVV), and KU Leuven IF STG/15/024 (GVV), MINECO SAF2016-79956-R (MD), and the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013–2017’, SEV-2012-0208
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction

  • Domingo Rodriguez, Laura, 1992-
  • Ruiz de Azua, Iñigo
  • Domínguez, Eduardo
  • Senabre, Eric
  • Serra, Irene
  • Kummer, Sami, 1985-
  • Navandar, Mohit
  • Baddenhausen, Sarah
  • Hofmann, Clementine
  • Andero, Raül
  • Gerber, Susanne
  • Navarrete, Marta
  • Dierssen, Mara
  • Lutz, Beat
  • Martín García, Elena, 1975-
  • Maldonado, Rafael, 1961-
Food addiction is linked to obesity and eating disorders and is characterized by a loss of behavioral control and compulsive food intake. Here, using a food addiction mouse model, we report that the lack of cannabinoid type-1 receptor in dorsal telencephalic glutamatergic neurons prevents the development of food addiction-like behavior, which is associated with enhanced synaptic excitatory transmission in the medial prefrontal cortex (mPFC) and in the nucleus accumbens (NAc). In contrast, chemogenetic inhibition of neuronal activity in the mPFC-NAc pathway induces compulsive food seeking. Transcriptomic analysis and genetic manipulation identified that increased dopamine D2 receptor expression in the mPFC-NAc pathway promotes the addiction-like phenotype. Our study unravels a new neurobiological mechanism underlying resilience and vulnerability to the development of food addiction, which could pave the way towards novel and efficient interventions for this disorder., This work was supported by the Spanish Ministerio de Economía y Competitividad-MINECO (#SAF2017-84060-R-AEI/FEDER-UE), the Spanish Instituto de Salud Carlos III, RETICS-RTA (#RD12/0028/0023), the Generalitat de Catalunya, AGAUR (#2017 SGR-669), ICREA-Acadèmia (#2015) and the Spanish Ministerio de Sanidad, Servicios Sociales e Igualdad, Plan Nacional Sobre Drogas (#PNSD-2017I068) to R.M., Fundació La Marató-TV3 (#2016/20-30) to E.M-G., the German Research Foundation (#CRC1193 “Neurobiology of Resilience”, TP A05 and B04) to B.L. and S.G., and the Boehringer Ingelheim Foundation to B.L., S.G. and I.R.A. The work of M.N.A was supported by the Emergent AI Center funded by the Carl-Zeiss-Stiftung. NARSAD Young Investigator Award (#22434), MINECO Ramón y Cajal (#RYC- 2014-15784) and (#SAF2016-76565-R) and Fondo Europeo de Desarrollo Regional (FEDER) to R.A. DIUE Generalitat de Catalunya (#2017 SGR 595), MINECO (#SAF2016-79956-R), EU (#Era Net Neuron PCIN-2013-060), Fundació La Marató-TV3 (#2016/20-31), CRG acknowledges support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Center of Excellence Severo Ochoa (#SEV-2012-0208), the CERCA Programme/Generalitat de Catalunya, the CIBER of Rare Diseases of the ISCIII to M.D. MINECO Ramón y Cajal (#RYC-2016-20414), AGAUR (#2017 SGR 926), (#RTI2018-094887-B-I00) and Fondo Europeo de Desarrollo Regional (FEDER) to M.N.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Protocol for measuring compulsive-like feeding behavior in mice

  • Fructuoso, Marta
  • Espinosa-Carrasco, José
  • Erb, Ionas
  • Notredame, Cedric
  • Dierssen, Mara
Obesity is an important health problem with a strong environmental component that is acquiring pandemic proportion. The high availability of caloric dense foods promotes overeating potentially causing obesity. Animal models are key to validate novel therapeutic strategies, but researchers must carefully select the appropriate model to draw the right conclusions. Obesity is defined by an increased body mass index greater than 30 and characterized by an excess of adipose issue. However, the regulation of food intake involves a close interrelationship between homeostatic and non-homeostatic factors. Studies in animal models have shown that intermittent access to sweetened or calorie-dense foods induces changes in feeding behavior. However, these studies are focused mainly on the final outcome (obesity) rather than on the primary dysfunction underlying the overeating of palatable foods. We describe a protocol to study overeating in mice using diet-induced obesity (DIO). This method can be applied to free choice between palatable food and a standard rodent chow or to forced intake of calorie-dense and/or palatable diets. Exposure to such diets is sufficient to promote changes in meal pattern that we register and analyze during the period of weight gain allowing the longitudinal characterization of feeding behavior in mice. Abnormal eating behaviors such as binge eating or snacking, behavioral alterations commonly observed in obese humans, can be detected using our protocol. In the free-choice procedure, mice develop a preference for the rewarding palatable food showing the reinforcing effect of this diet. Compulsive components of feeding are reflected by maintenance of feeding despite an adverse bitter taste caused by adulteration with quinine and by the negligence of standard chow when access to palatable food is ceased or temporally limited. Our strategy also enables to identify compulsive overeating in mice under a high-caloric regime by using limited food access and finally, we propose complementary behavioral tests to confirm the non-homeostatic food-taking triggered by these foods. Finally, we describe how to computationally explore large longitudinal behavioral datasets., This work was supported by Fondation Jérôme Lejeune (Paris, France), MINECO (SAF2016-79956-R), CDTI (‘Smartfoods’), EU (Era Net Neuron PCIN-2013-060) and the Catalan foundation ‘La Marató de TV3’ (#2016/20-30) and the EU Joint Programme–Neurodegenerative Disease Research (JPND) project under grant agreement HEROES AC17/00006. The CRG is a Center of Excellence Severo Ochoa SEV-2012-0208. The CIBER of Rare Diseases is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Time-course and dynamics of obesity-related behavioral changes induced by energy-dense foods in mice

  • Espinosa-Carrasco, José
  • Burokas, Aurelijus, 1982-
  • Fructuoso, Marta
  • Erb, Ionas
  • Martín García, Elena, 1975-
  • Gutiérrez Martos, Miriam, 1989-
  • Notredame, Cedric
  • Maldonado, Rafael, 1961-
  • Dierssen, Mara
Obesity represents an important risk factor contributing to the global burden of disease. The current obesogenic environment with easy access to calorie-dense foods is fueling this obesity epidemic. However, how these foods contribute to the progression of feeding behavior changes that lead to overeating is not well understood and needs systematic assessment. Using novel automated methods for the high-throughput screening of behavior, we here examine mice meal pattern upon long-term exposure to a free-choice chocolate-mixture diet and a high-fat diet with face validity for a rapid development of obesity induced by unhealthy food regularly consumed in our societies. We identified rapid diet-specific behavioral changes after exposure to those high-caloric diets. Mice fed with high-fat chow, showed long-lasting meal pattern disturbances, which initiate with a stable loss of circadian feeding rhythmicity. Mice receiving a chocolate-mixture showed qualitatively similar changes, though less marked, consisting in a transient disruption of the feeding behavior and the circadian feeding rhytmicity. Strikingly, compulsive-like eating behavior is triggered immediately after exposure to both high-fat food and chocolate-mixture diet, well before any changes in body weight could be observed. We propose these changes as behavioral biomarkers of prodromal states of obesity that could allow early intervention., The laboratory of M.D. is supported by DIUE de la Generalitat de Catalunya (Grups consolidats SGR 2014/1125). This work was supported by Fondation Jérôme Lejeune (Paris, France), MINECO (SAF2013‐49129‐C2‐1‐R; SAF2016‐79956‐R), CDTI ('Smartfoods') and EU (Era Net Neuron PCIN‐2013‐060) and the Catalan foundation 'La Marató de TV3' (#2016/20‐30). The CRG is a Center of Excellence Severo Ochoa SEV‐2012‐0208. The CIBER of Rare Diseases is an initiative of the ISCIII. The laboratory of C.N. acknowledge the funding from the Spanish Ministry of Economy and Finance (MINECO), grant number BFU2011‐28575. J.E. received the FI grant from Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya. The laboratory of R.M. was supported by the DG Research of the European Commission FP7 (#HEALTH‐F2 2013‐602891 and PHECOMP #LHSM‐CT‐2007‐037669), the Spanish 'RETICS‐Instituto de Salud Carlos III' (#RD16/0017/0020), the Spanish 'Ministerio de Economia y Competitividad' (#SAF‐2014‐59648P), the 'Plan nacional sobre drogas' (#PNSD‐2013‐5068), the Catalan Government 'AGAUR‐Generalitat de Catalunya' (#2014‐SGR‐1547) and the Catalan foundation 'La Marató de TV3' (#2016/20‐30).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Down syndrome is a metabolic disease: altered insulin signaling mediates peripheral and brain dysfunctions

  • Dierssen, Mara
  • Fructuoso, Marta
  • Martínez de Lagrán Cabredo, María
  • Perluigi, Marzia
  • Barone, Eugenio
Down syndrome (DS) is the most frequent chromosomal abnormality that causes intellectual disability, resulting from the presence of an extra complete or segment of chromosome 21 (HSA21). In addition, trisomy of HSA21 contributes to altered energy metabolism that appears to be a strong determinant in the development of pathological phenotypes associated with DS. Alterations include, among others, mitochondrial defects, increased oxidative stress levels, impaired glucose, and lipid metabolism, finally resulting in reduced energy production and cellular dysfunctions. These molecular defects seem to account for a high incidence of metabolic disorders, i.e., diabetes and/or obesity, as well as a higher risk of developing Alzheimer's disease (AD) in DS. A dysregulation of the insulin signaling with reduced downstream pathways represents a common pathophysiological aspect in the development of both peripheral and central alterations leading to diabetes/obesity and AD. This is further strengthened by evidence showing that the molecular mechanisms responsible for such alterations appear to be similar between peripheral organs and brain. Considering that DS subjects are at high risk to develop either peripheral or brain metabolic defects, this review will discuss current knowledge about the link between trisomy of HSA21 and defects of insulin and insulin-related pathways in DS. Drawing the molecular signature underlying these processes in DS is a key challenge to identify novel drug targets and set up new prevention strategies aimed to reduce the impact of metabolic disorders and cognitive decline., This work was supported by Fondi Ateneo grant funded by the Sapienza University n° RM11715C77336E99 to EB and n° C26H15JT9X to MP, Fondation Jérôme Lejeune (2019b – Project #1887) to EB; Fondation Jérôme Lejeune, MINECO (SAF2016-79956-R), H2020 SC1, GO-DS21- 848077, CDTI (“Smartfoods”), Fundació La Marató De TV3 (201620-31_MDierssen), and JPND HEROES (tHE cRossroad Of dEmentia Syndromes to MD). The CRG was a Center of Excellence Severo Ochoa SEV-2016-0571.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

DYRK1A overexpression alters cognition and neural-related proteomic pathways in the hippocampus that are rescued by green tea extract and/or environmental enrichment

  • De Toma, Ilario
  • Ortega Crespo, Mireia, 1988-
  • Aloy, Patrick, 1972-
  • Sabidó Aguadé, Eduard, 1981-
  • Dierssen, Mara
Down syndrome (DS), caused by trisomy of chromosome 21, is the most common genetic cause of intellectual disability. We recently discovered that green tea extracts containing epigallocatechin-3-gallate (EGCG) improve cognition in mice transgenic for Dyrk1a (TgDyrk1A) and in a trisomic DS mouse model (Ts65Dn). Interestingly, paired with cognitive stimulation, green tea has beneficial pro-cognitive effects in DS individuals. Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (DYRK1A) is a major candidate to explain the cognitive phenotypes of DS, and inhibiting its activity is a promising pro-cognitive therapy. DYRK1A kinase activity can be normalized in the hippocampus of transgenic DYRK1A mice administering green tea extracts, but also submitting the animals to environmental enrichment (EE). However, many other mechanisms could also explain the pro-cognitive effects of green tea extracts and EE. To underpin the overall alterations arising upon DYRK1A overexpression and the molecular processes underneath the pro-cognitive effects, we used quantitative proteomics. We investigated the hippocampal (phospho)proteome in basal conditions and after treatment with a green tea extract containing EGCG and/or EE in TgDyrk1A and control mice. We found that Dyrk1A overexpression alters protein and phosphoprotein levels of key postsynaptic and plasticity-related pathways and that these alterations were rescued upon the cognitive enhancer treatments., The work has received financial support from MINECO (SAF2016-79956-R), Jerome Lejeune Foundation (Project #1347 “Elucidation of the mechanism of action of epigallocatechin-3-gallate as a therapeutic agent on the cognitive phenotype in Down Syndrome mice models”), and the NIH 1R01EB 028159-01 to MD, the Centre for Genomic Regulation Severo Ochoa excellence grant (SEV-2012-0208), the Centro de Investigación Biomédica en Red Enfermedades Raras (CIBER) of Rare Diseases; “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (Grups consolidats SGR 2016/1125, and 2017SGR595); and the “Centro para el Desarrollo Tecnológico Industrial CDTI.” The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of Proteored, PRB3, and is supported by grant PT17/0019, of the PE I+D+i 2013–2016, funded by ISCIII. ID received funding from the People Program (Marie Curie Actions) of the European Union’s Seventh Framework Program (FP7/2007-2013) under REA grant agreement n° 608959. MO received an FPI Severo Ochoa Doctoral Fellowship from the Spanish Ministry of Economy and Finance (MINECO) SVP-2013-068022 during the period 2014–2018 and a short research international stay fellowship (EEBB-I-16-11305).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mutations in L-type amino acid transporter-2 support SLC7A8 as a novel gene involved in age-related hearing loss

  • Espino Guarch, Meritxell
  • Font-Llitjós, Mariona
  • Murillo-Cuesta, Silvia
  • Errasti-Murugarren, Ekaitz
  • Celaya, Adelaida M.
  • Girotto, Giorgia
  • Vuckovic, Dragana
  • Mezzavilla, Massimo
  • Vilches, Clara
  • Bodoy, Susanna
  • Sahún, Ignasi
  • González, Laura
  • Prat, Esther
  • Zorzano, Antonio
  • Dierssen, Mara
  • Varela-Nieto, Isabel
  • Gasparini, Paolo
  • Palacín, Manuel
  • Nunes, Virginia
Age-related hearing loss (ARHL) is the most common sensory deficit in the elderly. The disease has a multifactorial etiology with both environmental and genetic factors involved being largely unknown. SLC7A8/SLC3A2 heterodimer is a neutral amino acid exchanger. Here, we demonstrated that SLC7A8 is expressed in the mouse inner ear and that its ablation resulted in ARHL, due to the damage of different cochlear structures. These findings make SLC7A8 transporter a strong candidate for ARHL in humans. Thus, a screening of a cohort of ARHL patients and controls was carried out revealing several variants in SLC7A8, whose role was further investigated by in vitro functional studies. Significant decreases in SLC7A8 transport activity was detected for patient's variants (p.Val302Ile, p.Arg418His, p.Thr402Met and p.Val460Glu) further supporting a causative role for SLC7A8 in ARHL. Moreover, our preliminary data suggest that a relevant proportion of ARHL cases could be explained by SLC7A8 mutations., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction

  • Domingo-Rodriguez, L.
  • Ruiz de Azua, I.
  • Domínguez, Eduardo
  • Senabre, E.
  • Serra, Irene
  • Kummer, S.
  • Navandar, M.
  • Baddenhausen, S.
  • Hofmann, C.
  • Andero, R
  • Gerber, S.
  • Navarrete, Marta
  • Dierssen, Mara
  • Lutz, Beat
  • Martín-García, Elena
  • Maldonado, Rafael
Food addiction is linked to obesity and eating disorders and is characterized by a loss of behavioral control and compulsive food intake. Here, using a food addiction mouse model, we report that the lack of cannabinoid type-1 receptor in dorsal telencephalic glutamatergic neurons prevents the development of food addiction-like behavior, which is associated with enhanced synaptic excitatory transmission in the medial prefrontal cortex (mPFC) and in the nucleus accumbens (NAc). In contrast, chemogenetic inhibition of neuronal activity in the mPFC-NAc pathway induces compulsive food seeking. Transcriptomic analysis and genetic manipulation identified that increased dopamine D2 receptor expression in the mPFC-NAc pathway promotes the addiction-like phenotype. Our study unravels a new neurobiological mechanism underlying resilience and vulnerability to the development of food addiction, which could pave the way towards novel and efficient interventions for this disorder., This work was supported by the Spanish Ministerio de Economía y Competitividad-MINECO (#SAF2017-84060-R-AEI/FEDER-UE), the Spanish Instituto de Salud Carlos III, RETICS-RTA (#RD12/0028/0023), the Generalitat de Catalunya, AGAUR (#2017 SGR-669), ICREA-Acadèmia (#2015) and the Spanish Ministerio de Sanidad, Servicios Sociales e Igualdad, Plan Nacional Sobre Drogas (#PNSD-2017I068) to R.M., Fundació La Marató-TV3 (#2016/20-30) to E.M-G., the German Research Foundation (#CRC1193 “Neurobiology of Resilience”, TP A05 and B04) to B.L. and S.G., and the Boehringer Ingelheim Foundation to B.L., S.G. and I.R.A. The work of M.N.A was supported by the Emergent AI Center funded by the Carl-Zeiss-Stiftung. NARSAD Young Investigator Award (#22434), MINECO Ramón y Cajal (#RYC- 2014-15784) and (#SAF2016-76565-R) and Fondo Europeo de Desarrollo Regional (FEDER) to R.A. DIUE Generalitat de Catalunya (#2017 SGR 595), MINECO (#SAF2016-79956-R), EU (#Era Net Neuron PCIN-2013-060), Fundació La Marató-TV3 (#2016/20-31), CRG acknowledges support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Center of Excellence Severo Ochoa (#SEV-2012-0208), the CERCA Programme/Generalitat de Catalunya, the CIBER of Rare Diseases of the ISCIII to M.D. MINECO Ramón y Cajal (#RYC-2016-20414), AGAUR (#2017 SGR 926), (#RTI2018-094887-B-I00) and Fondo Europeo de Desarrollo Regional (FEDER) to M.N.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pergola: boosting visualization and analysis of longitudinal data by unlocking genomic analysis tools

  • Espinosa-Carrasco, José
  • Erb, Ionas
  • Hermoso Pulido, Antonio
  • Ponomarenko, Julia
  • Dierssen, Mara
  • Notredame, Cedric
The growing appetite of behavioral neuroscience for automated data production is prompting the need for new computational standards allowing improved interoperability, reproducibility, and shareability. We show here how these issues can be solved by repurposing existing genomic formats whose structure perfectly supports the handling of time series. This allows existing genomic analysis and visualization tools to be deployed onto behavioral data. As a proof of principle, we implemented the conversion procedure in Pergola, an open source software, and used genomics tools to reproduce results obtained in mouse, fly, and worm. We also show how common genomics techniques such as principal component analysis, hidden Markov modeling, and volcano plots can be deployed on the reformatted behavioral data. These analyses are easy to share because they depend on the scripting of public software. They are also easy to reproduce thanks to their integration within Nextflow, a workflow manager using containerized software., We acknowledge the support of the “Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat i del Fons Social Europeu,” Spanish Ministry of Economy, Industry and Competitiveness (MEIC) under grant numbers BFU2014-55062-P and BFU2017-88264-P, the EMBL partnership, FEDER, the “Centro de Excelencia Severo Ochoa” Programme, and the CERCA Programme/Generalitat de Catalunya. This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 635290-PanCanRisk and OpenRiskNet_731076. This reflects only the author's view and the funder is not responsible for any use that may be made of the information it contains. M.D. is supported by DIUE de la Generalitat de Catalunya (Grups consolidats SGR 2017/926), the Fondation Jérôme Lejeune (Paris, France), MINECO (SAF2013-49129-C2-1-R; SAF2016-79956-R), CDTI (“Smartfoods”) and EU (EraNet Neuron PCIN-2013-060 and JPND AC17/00006), and the Catalan foundation “La Marató de TV3” (#2016/20-30). The CIBER of Rare Diseases is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Down syndrome is a metabolic disease: altered insulin signaling mediates peripheral and brain dysfunctions

  • Dierssen, Mara
  • Fructuoso, Marta
  • Martínez de Lagrán Cabredo, María
  • Perluigi, Marzia
  • Barone, Eugenio
Down syndrome (DS) is the most frequent chromosomal abnormality that causes intellectual disability, resulting from the presence of an extra complete or segment of chromosome 21 (HSA21). In addition, trisomy of HSA21 contributes to altered energy metabolism that appears to be a strong determinant in the development of pathological phenotypes associated with DS. Alterations include, among others, mitochondrial defects, increased oxidative stress levels, impaired glucose, and lipid metabolism, finally resulting in reduced energy production and cellular dysfunctions. These molecular defects seem to account for a high incidence of metabolic disorders, i.e., diabetes and/or obesity, as well as a higher risk of developing Alzheimer's disease (AD) in DS. A dysregulation of the insulin signaling with reduced downstream pathways represents a common pathophysiological aspect in the development of both peripheral and central alterations leading to diabetes/obesity and AD. This is further strengthened by evidence showing that the molecular mechanisms responsible for such alterations appear to be similar between peripheral organs and brain. Considering that DS subjects are at high risk to develop either peripheral or brain metabolic defects, this review will discuss current knowledge about the link between trisomy of HSA21 and defects of insulin and insulin-related pathways in DS. Drawing the molecular signature underlying these processes in DS is a key challenge to identify novel drug targets and set up new prevention strategies aimed to reduce the impact of metabolic disorders and cognitive decline., This work was supported by Fondi Ateneo grant funded by the Sapienza University n° RM11715C77336E99 to EB and n° C26H15JT9X to MP, Fondation Jérôme Lejeune (2019b – Project #1887) to EB; Fondation Jérôme Lejeune, MINECO (SAF2016-79956-R), H2020 SC1, GO-DS21- 848077, CDTI (“Smartfoods”), Fundació La Marató De TV3 (201620-31_MDierssen), and JPND HEROES (tHE cRossroad Of dEmentia Syndromes to MD). The CRG was a Center of Excellence Severo Ochoa SEV-2016-0571.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Time-course and dynamics of obesity-related behavioral changes induced by energy-dense foods in mice

  • Espinosa-Carrasco, José
  • Burokas, Aurelijus, 1982-
  • Fructuoso, Marta
  • Erb, Ionas
  • Martín García, Elena, 1975-
  • Gutiérrez Martos, Miriam, 1989-
  • Notredame, Cedric
  • Maldonado, Rafael, 1961-
  • Dierssen, Mara
Obesity represents an important risk factor contributing to the global burden of disease. The current obesogenic environment with easy access to calorie-dense foods is fueling this obesity epidemic. However, how these foods contribute to the progression of feeding behavior changes that lead to overeating is not well understood and needs systematic assessment. Using novel automated methods for the high-throughput screening of behavior, we here examine mice meal pattern upon long-term exposure to a free-choice chocolate-mixture diet and a high-fat diet with face validity for a rapid development of obesity induced by unhealthy food regularly consumed in our societies. We identified rapid diet-specific behavioral changes after exposure to those high-caloric diets. Mice fed with high-fat chow, showed long-lasting meal pattern disturbances, which initiate with a stable loss of circadian feeding rhythmicity. Mice receiving a chocolate-mixture showed qualitatively similar changes, though less marked, consisting in a transient disruption of the feeding behavior and the circadian feeding rhytmicity. Strikingly, compulsive-like eating behavior is triggered immediately after exposure to both high-fat food and chocolate-mixture diet, well before any changes in body weight could be observed. We propose these changes as behavioral biomarkers of prodromal states of obesity that could allow early intervention., The laboratory of M.D. is supported by DIUE de la Generalitat de Catalunya (Grups consolidats SGR 2014/1125). This work was supported by Fondation Jérôme Lejeune (Paris, France), MINECO (SAF2013‐49129‐C2‐1‐R; SAF2016‐79956‐R), CDTI ('Smartfoods') and EU (Era Net Neuron PCIN‐2013‐060) and the Catalan foundation 'La Marató de TV3' (#2016/20‐30). The CRG is a Center of Excellence Severo Ochoa SEV‐2012‐0208. The CIBER of Rare Diseases is an initiative of the ISCIII. The laboratory of C.N. acknowledge the funding from the Spanish Ministry of Economy and Finance (MINECO), grant number BFU2011‐28575. J.E. received the FI grant from Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) de la Generalitat de Catalunya. The laboratory of R.M. was supported by the DG Research of the European Commission FP7 (#HEALTH‐F2 2013‐602891 and PHECOMP #LHSM‐CT‐2007‐037669), the Spanish 'RETICS‐Instituto de Salud Carlos III' (#RD16/0017/0020), the Spanish 'Ministerio de Economia y Competitividad' (#SAF‐2014‐59648P), the 'Plan nacional sobre drogas' (#PNSD‐2013‐5068), the Catalan Government 'AGAUR‐Generalitat de Catalunya' (#2014‐SGR‐1547) and the Catalan foundation 'La Marató de TV3' (#2016/20‐30).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

DYRK1A overexpression alters cognition and neural-related proteomic pathways in the hippocampus that are rescued by green tea extract and/or environmental enrichment

  • De Toma, Ilario
  • Ortega Crespo, Mireia, 1988-
  • Aloy, Patrick, 1972-
  • Sabidó Aguadé, Eduard, 1981-
  • Dierssen, Mara
Down syndrome (DS), caused by trisomy of chromosome 21, is the most common genetic cause of intellectual disability. We recently discovered that green tea extracts containing epigallocatechin-3-gallate (EGCG) improve cognition in mice transgenic for Dyrk1a (TgDyrk1A) and in a trisomic DS mouse model (Ts65Dn). Interestingly, paired with cognitive stimulation, green tea has beneficial pro-cognitive effects in DS individuals. Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A (DYRK1A) is a major candidate to explain the cognitive phenotypes of DS, and inhibiting its activity is a promising pro-cognitive therapy. DYRK1A kinase activity can be normalized in the hippocampus of transgenic DYRK1A mice administering green tea extracts, but also submitting the animals to environmental enrichment (EE). However, many other mechanisms could also explain the pro-cognitive effects of green tea extracts and EE. To underpin the overall alterations arising upon DYRK1A overexpression and the molecular processes underneath the pro-cognitive effects, we used quantitative proteomics. We investigated the hippocampal (phospho)proteome in basal conditions and after treatment with a green tea extract containing EGCG and/or EE in TgDyrk1A and control mice. We found that Dyrk1A overexpression alters protein and phosphoprotein levels of key postsynaptic and plasticity-related pathways and that these alterations were rescued upon the cognitive enhancer treatments., The work has received financial support from MINECO (SAF2016-79956-R), Jerome Lejeune Foundation (Project #1347 “Elucidation of the mechanism of action of epigallocatechin-3-gallate as a therapeutic agent on the cognitive phenotype in Down Syndrome mice models”), and the NIH 1R01EB 028159-01 to MD, the Centre for Genomic Regulation Severo Ochoa excellence grant (SEV-2012-0208), the Centro de Investigación Biomédica en Red Enfermedades Raras (CIBER) of Rare Diseases; “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (Grups consolidats SGR 2016/1125, and 2017SGR595); and the “Centro para el Desarrollo Tecnológico Industrial CDTI.” The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of Proteored, PRB3, and is supported by grant PT17/0019, of the PE I+D+i 2013–2016, funded by ISCIII. ID received funding from the People Program (Marie Curie Actions) of the European Union’s Seventh Framework Program (FP7/2007-2013) under REA grant agreement n° 608959. MO received an FPI Severo Ochoa Doctoral Fellowship from the Spanish Ministry of Economy and Finance (MINECO) SVP-2013-068022 during the period 2014–2018 and a short research international stay fellowship (EEBB-I-16-11305).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome

  • Navarro-Romero, Alba
  • Vázquez-Oliver, Anna
  • Gomis González, Maria, 1988-
  • Garzón-Montesinos, Carlos
  • Falcón-Moya, Rafael
  • Pastor, Antonio
  • Martín García, Elena, 1975-
  • Pizarro Lozano, Mª Nieves
  • Busquets Garcia, Arnau, 1985-
  • Revest, Jean-Michel
  • Piazza, Pier Vincenzo
  • Bosch, Fatima
  • Dierssen, Mara
  • Torre Fornell, Rafael de la
  • Rodríguez-Moreno, Antonio
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Intellectual disability is the most limiting hallmark of Down syndrome, for which there is no gold-standard clinical treatment yet. The endocannabinoid system is a widespread neuromodulatory system involved in multiple functions including learning and memory processes. Alterations of this system contribute to the pathogenesis of several neurological and neurodevelopmental disorders. However, the involvement of the endocannabinoid system in the pathogenesis of Down syndrome has not been explored before. We used the best-characterized preclinical model of Down syndrome, the segmentally trisomic Ts65Dn model. In male Ts65Dn mice, cannabinoid type-1 receptor (CB1R) expression was enhanced and its function increased in hippocampal excitatory terminals. Knockdown of CB1R in the hippocampus of male Ts65Dn mice restored hippocampal-dependent memory. Concomitant with this result, pharmacological inhibition of CB1R restored memory deficits, hippocampal synaptic plasticity and adult neurogenesis in the subgranular zone of the dentate gyrus. Notably, the blockade of CB1R also normalized hippocampal-dependent memory in female Ts65Dn mice. To further investigate the mechanisms involved, we used a second transgenic mouse model overexpressing a single gene candidate for Down syndrome cognitive phenotypes, the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). CB1R pharmacological blockade similarly improved cognitive performance, synaptic plasticity and neurogenesis in transgenic male Dyrk1A mice. Our results identify CB1R as a novel druggable target potentially relevant for the improvement of cognitive deficits associated with Down syndrome., A.N.-R. is the recipient of a predoctoral fellowship (Ministerio de Educación y Cultura, Spain). A.V.-O. is the recipient of a predoctoral fellowship from Jérôme Lejeune Foundation, France (Spanish Delegation). M.G.-G. was partially supported by FRAXA Research Foundation, United States. A.B-G. was the recipient of a predoctoral fellowship (Ministerio de Educación y Cultura). This study was supported by Jérôme Lejeune Foundation (French Delegation) to A.O.; Instituto de Salud Carlos III, Spain (#RD16/0017/0020) to R.M.; Ministerio de Economía, Innovación y Competitividad (MINECO), Spain (#BFU2015-68568-P to A.O., #SAF2014-59648-P and #SAF2017- 84060-R to R.M.; SAF2016-79956-R to M.D.); Catalan Foundation ‘La Marató de TV3’, Spain (#2016/20-30) to E.M.-G.; Junta de Andalucía, Spain (CVI-7290 to A.R.-M.); Generalitat de Catalunya, Spain (2014SGR-1547 and 2017SGR-669 to R.M.; 2014SGR-1125 to M.D.) and ICREA (Institució Catalana de Recerca i Estudis Avançats, Spain) Academia to A.O. and R.M. Grant “Unidad de Excelencia María de Maeztu”, funded by the MINECO (#MDM-2014-0370); PLAN E, Spain (Plan Español para el Estímulo de la Economía y el Empleo); FEDER, European Commission funding is also acknowledged
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome

  • Torre Fornell, Rafael de la
  • De Sola Llopis, Susana
  • Xicota Vila, Laura, 1987-
  • Cuenca Royo, Aida Ma, 1981-
  • Rodriguez, Joan
  • Gomis González, Maria, 1988-
  • Hernández, Gimena
  • Del Hoyo Soriano, Laura
  • Ozaita Mintegui, Andrés, 1969-
  • Dierssen, Mara
  • TESXF Study Group
  • Principe, Alessandro
  • Espadaler, Josep María
  • Roca, Laia
  • Del Hoyo Soriano, Laura
  • Farré Albaladejo, Magí
  • Fitó Colomer, Montserrat
  • León Jorba, Alba
  • Banea, Ovideo
  • Maldonado, Rafael, 1961-
  • Busquets Garcia, Arnau, 1985-
Background & aims: Despite the wide spectrum of experimental compounds tested in clinical trials, there is still no proven pharmacological treatment available for Fragile-X syndrome (FXS), since several targeted clinical trials with high expectations of success have failed to demonstrate significant improvements. Here we tested epigallocatechin-3-gallate (EGCG) as a treatment option for ameliorating core cognitive and behavioral features in FXS. Methods: We conducted preclinical studies in Fmr1 knockout mice (Fmr1−/y) using novel object-recognition memory paradigm upon acute EGCG (10 mg/kg) administration. Furthermore we conducted a double-blind placebo-controlled phase I clinical trial (TESXF; NCT01855971). Twenty-seven subjects with FXS (18–55 years) were administered of EGCG (5–7 mg/kg/day) combined with cognitive training (CT) during 3 months with 3 months of follow-up after treatment discontinuation. Results: Preclinical studies showed an improvement in memory using the Novel Object Recognition paradigm. We found that FXS patients receiving EGCG + CT significantly improved cognition (visual episodic memory) and functional competence (ABAS II-Home Living skills) in everyday life compared to subjects receiving Placebo + CT. Conclusions: Phase 2 clinical trials in larger groups of subjects are necessary to establish the therapeutic potential of EGCG for the improvement of cognition and daily life competences in FXS., This work was supported by the Spanish Ministry of Economy and Competitiveness; ‘Centro de Excelencia Severo Ochoa 2013-2017’; the ‘Centres de Recerca de Catalunya’ Programme / Generalitat de Catalunya’; the Centro de Investigación Biomédica en Red Enfermedades Raras (CIBER) of Rare Diseases; DIUE de la Generalitat de Catalunya [Grups consolidats SGR 2014/1125]; Ministerio de Economía, Industria y Competitividad de España MINECO [SAF2013-49129-C2-1-R and SAF2016-79956-R].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pergola-web: a web server for the visualization and analysis of longitudinal behavioral data using repurposed genomics tools and standards

  • Espinosa-Carrasco, José
  • Hermoso Pulido, Antonio
  • Erb, Ionas
  • Dierssen, Mara
  • Ponomarenko, Julia
  • Notredame, Cedric
We present a new web application to query and visualize time-series behavioral data: the Pergola web-server. This server provides a user-friendly interface for exploring longitudinal behavioral data taking advantage of the Pergola Python library. Using the server, users can process the data applying some basic operations, such as binning or grouping, while formatting the data into existing genomic formats. Thanks to this repurposing of genomics standards, the application automatically renders an interactive data visualization based on sophisticated genome visualization tools. Our tool allows behavioral scientists to share, display and navigate complex behavioral data comprising multiple individuals and multiple data types, in a scalable and flexible manner. A download option allows for further analysis using genomic tools. The server can be a great resource for the field in a time where behavioral science is entering a data-intensive cycle thanks to high-throughput behavioral phenotyping platforms. Pergola is publicly available at http://pergola.crg.eu/., 'Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat i del Fons Social Europeu', Spanish Ministry of Economy, Industry and Competitiveness (MEIC) [BFU2014-55062-P, BFU2017-88264-P]; EMBL partnership, FEDER, the ‘Centro de Excelencia Severo Ochoa’ Programme; CERCA Programme/Generalitatde Catalunya; European Union's Horizon 2020 research and innovation program [635290-PanCanRisk and OpenRiskNet_731076]; DIUE de la Generalitat de Catalunya [Grups consolidatsSGR 2017/926]; Fondation Jérôme Lejeune (Paris, France), MINECO [SAF2013-49129-C2-1-R;SAF2016-79956-R]; CDTI (‘Smartfoods’) and EU [EraNet Neuron PCIN-2013-060 and JPND AC17/00006]; Catalan foundation ‘La Marato′de TV3’ [2016/20-30]; CIBER of Rare Diseases is an initiative of the ISCIII. Funding for open access charge: CRG institutional core funding.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Protocol for measuring compulsive-like feeding behavior in mice

  • Fructuoso, Marta
  • Espinosa-Carrasco, José
  • Erb, Ionas
  • Notredame, Cedric
  • Dierssen, Mara
Obesity is an important health problem with a strong environmental component that is acquiring pandemic proportion. The high availability of caloric dense foods promotes overeating potentially causing obesity. Animal models are key to validate novel therapeutic strategies, but researchers must carefully select the appropriate model to draw the right conclusions. Obesity is defined by an increased body mass index greater than 30 and characterized by an excess of adipose issue. However, the regulation of food intake involves a close interrelationship between homeostatic and non-homeostatic factors. Studies in animal models have shown that intermittent access to sweetened or calorie-dense foods induces changes in feeding behavior. However, these studies are focused mainly on the final outcome (obesity) rather than on the primary dysfunction underlying the overeating of palatable foods. We describe a protocol to study overeating in mice using diet-induced obesity (DIO). This method can be applied to free choice between palatable food and a standard rodent chow or to forced intake of calorie-dense and/or palatable diets. Exposure to such diets is sufficient to promote changes in meal pattern that we register and analyze during the period of weight gain allowing the longitudinal characterization of feeding behavior in mice. Abnormal eating behaviors such as binge eating or snacking, behavioral alterations commonly observed in obese humans, can be detected using our protocol. In the free-choice procedure, mice develop a preference for the rewarding palatable food showing the reinforcing effect of this diet. Compulsive components of feeding are reflected by maintenance of feeding despite an adverse bitter taste caused by adulteration with quinine and by the negligence of standard chow when access to palatable food is ceased or temporally limited. Our strategy also enables to identify compulsive overeating in mice under a high-caloric regime by using limited food access and finally, we propose complementary behavioral tests to confirm the non-homeostatic food-taking triggered by these foods. Finally, we describe how to computationally explore large longitudinal behavioral datasets., This work was supported by Fondation Jérôme Lejeune (Paris, France), MINECO (SAF2016-79956-R), CDTI (‘Smartfoods’), EU (Era Net Neuron PCIN-2013-060) and the Catalan foundation ‘La Marató de TV3’ (#2016/20-30) and the EU Joint Programme–Neurodegenerative Disease Research (JPND) project under grant agreement HEROES AC17/00006. The CRG is a Center of Excellence Severo Ochoa SEV-2012-0208. The CIBER of Rare Diseases is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome

  • Starbuck, John M.
  • Llambrich, Sergi
  • González, Rubén
  • Albaigès-Ràfols, Júlia
  • Sarlé, Anna
  • Wouters, Jens
  • González, Alejandro
  • Sevillano, Xavier
  • Sharpe, James
  • Torre Fornell, Rafael de la
  • Dierssen, Mara
  • Velde, Greetje Vande
  • Martínez Abadías, Neus
Trisomy of human chromosome 21 (Down syndrome, DS) alters development of multiple organ systems, including the face and underlying skeleton. Besides causing stigmata, these facial dysmorphologies can impair vital functions such as hearing, breathing, mastication, and health. To investigate the therapeutic potential of green tea extracts containing epigallocatechin-3-gallate (GTE-EGCG) for alleviating facial dysmorphologies associated with DS, we performed an experimental study with continued pre- and postnatal treatment with two doses of GTE-EGCG supplementation in a mouse model of DS, and an observational study of children with DS whose parents administered EGCG as a green tea supplement. We evaluated the effect of high (100 mg/kg/day) or low doses (30 mg/kg/day) of GTE-EGCG, administered from embryonic day 9 to post-natal day 29, on the facial skeletal development in the Ts65Dn mouse model. In a cross-sectional observational study, we assessed the facial shape in DS and evaluated the effects of self-medication with green tea extracts in children from 0 to 18 years old. The main outcomes are 3D quantitative morphometric measures of the face, acquired either with micro-computed tomography (animal study) or photogrammetry (human study). The lowest experimentally tested GTE-EGCG dose improved the facial skeleton morphology in a mouse model of DS. In humans, GTE-EGCG supplementation was associated with reduced facial dysmorphology in children with DS when treatment was administered during the first 3 years of life. However, higher GTE-EGCG dosing disrupted normal development and increased facial dysmorphology in both trisomic and euploid mice. We conclude that GTE-EGCG modulates facial development with dose-dependent effects. Considering the potentially detrimental effects observed in mice, the therapeutic relevance of controlled GTE-EGCG administration towards reducing facial dysmorphology in young children with Down syndrome has yet to be confirmed by clinical studies., We acknowledge support from a 2016 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation IN[16]_CMA_BIO_0096 (NMA). We also acknowledge grant support from the following: CRG Awards for Collaborative Research Proposals, CRG Awards 2015-005822 (NMA, JA), Marguerite-Marie Delacroix Foundation fellowship (SL), Jerome Lejeune Foundation, #1782 (GVV, NMA), University of Central Florida start-up funds (JMS), American Association of Physical Anthropologists Professional Development Program Grant (JMS), Flemish Research Foundation (FWO) fellowship (GVV), and KU Leuven IF STG/15/024 (GVV), MINECO SAF2016-79956-R (MD), and the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013–2017’, SEV-2012-0208
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction

  • Domingo Rodriguez, Laura, 1992-
  • Ruiz de Azua, Iñigo
  • Domínguez, Eduardo
  • Senabre, Eric
  • Serra, Irene
  • Kummer, Sami, 1985-
  • Navandar, Mohit
  • Baddenhausen, Sarah
  • Hofmann, Clementine
  • Andero, Raül
  • Gerber, Susanne
  • Navarrete, Marta
  • Dierssen, Mara
  • Lutz, Beat
  • Martín García, Elena, 1975-
  • Maldonado, Rafael, 1961-
Food addiction is linked to obesity and eating disorders and is characterized by a loss of behavioral control and compulsive food intake. Here, using a food addiction mouse model, we report that the lack of cannabinoid type-1 receptor in dorsal telencephalic glutamatergic neurons prevents the development of food addiction-like behavior, which is associated with enhanced synaptic excitatory transmission in the medial prefrontal cortex (mPFC) and in the nucleus accumbens (NAc). In contrast, chemogenetic inhibition of neuronal activity in the mPFC-NAc pathway induces compulsive food seeking. Transcriptomic analysis and genetic manipulation identified that increased dopamine D2 receptor expression in the mPFC-NAc pathway promotes the addiction-like phenotype. Our study unravels a new neurobiological mechanism underlying resilience and vulnerability to the development of food addiction, which could pave the way towards novel and efficient interventions for this disorder., This work was supported by the Spanish Ministerio de Economía y Competitividad-MINECO (#SAF2017-84060-R-AEI/FEDER-UE), the Spanish Instituto de Salud Carlos III, RETICS-RTA (#RD12/0028/0023), the Generalitat de Catalunya, AGAUR (#2017 SGR-669), ICREA-Acadèmia (#2015) and the Spanish Ministerio de Sanidad, Servicios Sociales e Igualdad, Plan Nacional Sobre Drogas (#PNSD-2017I068) to R.M., Fundació La Marató-TV3 (#2016/20-30) to E.M-G., the German Research Foundation (#CRC1193 “Neurobiology of Resilience”, TP A05 and B04) to B.L. and S.G., and the Boehringer Ingelheim Foundation to B.L., S.G. and I.R.A. The work of M.N.A was supported by the Emergent AI Center funded by the Carl-Zeiss-Stiftung. NARSAD Young Investigator Award (#22434), MINECO Ramón y Cajal (#RYC- 2014-15784) and (#SAF2016-76565-R) and Fondo Europeo de Desarrollo Regional (FEDER) to R.A. DIUE Generalitat de Catalunya (#2017 SGR 595), MINECO (#SAF2016-79956-R), EU (#Era Net Neuron PCIN-2013-060), Fundació La Marató-TV3 (#2016/20-31), CRG acknowledges support of the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) to the EMBL partnership, the Center of Excellence Severo Ochoa (#SEV-2012-0208), the CERCA Programme/Generalitat de Catalunya, the CIBER of Rare Diseases of the ISCIII to M.D. MINECO Ramón y Cajal (#RYC-2016-20414), AGAUR (#2017 SGR 926), (#RTI2018-094887-B-I00) and Fondo Europeo de Desarrollo Regional (FEDER) to M.N.